Acadia Pharmaceuticals (ACAD) Stock: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$20.19
-0.25 (-1.22%)
▼
5d:
+4.88%
30d:
-23.55%
90d:
-18.69%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 04, 2026
13d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Oct 15, 2026 at $19.71 · last confirmed Oct 15, 2026
Strength: 5.9/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACAD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ACAD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$44.82
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$27.83
27.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $20.19, which is considered slightly low relative to its 30-day fair value range of $18.73 to $25.12. From a valuation perspective, the stock is trading at a discount (Forward PE: 21.9) compared to its historical average (27.8). Remarkably, the market is currently pricing in an annual earnings decline of 7.6% over the next few years. This pessimistic expectation contrasts with the company's recent 13.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ACAD is showing sideways momentum. The price is approaching resistance at $20.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACAD scores 93/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.53 (+51.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACAD is showing sideways momentum. The price is approaching resistance at $20.57. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ACAD scores 93/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $30.53 (+51.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$18.73 -
$25.12
Company Quality Score
71/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
90.5%
Protect Your Profits
Holding ACAD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (93/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 51.2% below Wall St target ($30.53)
- CAUTION: Bottoming setup, but lagging the sector by 13% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$18.73 -
$25.12
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$18.39
Resistance Level
$20.57
Current Trend
Sideways
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
21.93
Wall Street Target
$30.53
(+51.2%)
Revenue Growth (YoY)
16.4%
Earnings Growth (YoY)
13.3%
Profit Margin
33.4%
Valuation Discount vs History
-7.6% cheaper
PE vs Historical
21.9 vs 27.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.6%
(market-implied from PE analysis)
1-Year Target
$18.66
(-8%)
2-Year Target
$17.24
(-15%)
3-Year Target
$15.93
(-21%)
3-Yr Target (if PE normalizes)
(PE: 22→28)
$20.19
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 54.7%)
$68.14
(+238%)
Base:
(SPY PE: 19.9, Growth: 54.7%)
$61.71
(+206%)
Bear:
(PE: 16.9, Growth: 54.7%)
$52.46
(+160%)
📈
Valuation based on Current Earnings
Trailing PE: 8.89 | Current EPS (TTM): $2.30
Bull Case
$11.24
(-44%)
Analyst growth -50.0%, PE expands to 9.8
Base Case
$10.22
(-49%)
Market implied -50.0%, PE stable at 8.9
Bear Case
$13.90
(-31%)
Severe decline -20.0%, PE contracts to 7.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.9 to 27.8
Stabilization Target:
$25.60
(+26.8%)
PE Expansion Potential:
+26.8%
Share & Embed Analysis
Last updated: October 21, 2026 6:13 PM ET
Data refreshes hourly during market hours. Next update: 7:13 PM
Data refreshes hourly during market hours. Next update: 7:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 58 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 54 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 55 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 59 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 61 BUY |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
